AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B at FLORetina 2024 AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa USH1B

AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting

AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study